About 3 results found for searched term "JAK-IN-5 hydrochloride" (0.121 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M49551 | JAK-IN-5 hydrochloride | JAK |
| JAK-IN-5 hydrochloride is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283. | ||
| M27991 | Pacritinib hydrochloride | JAK |
| SB-1518 hydrochloride | ||
| Pacritinib hydrochloride is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2V617F mutant (IC50=19 nM). Pacritinib hydrochloride also inhibits FLT3 (IC50=22 nM) and its mutant FLT3D835Y (IC50=6 nM). Pacritinib hydrochloride can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF). | ||
| M28279 | Fedratinib hydrochloride hydrate | JAK |
| TG-101348 hydrochloride hydrate; SAR 302503 hydrochloride hydrate | ||
| Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
